A deal for Merck's COVID-19 pill to be made and sold cheaply in poor nations has been reached with Medicines Patent Pool, a United Nations-backed nonprofit organization.
The royalty-free license means that companies in 105 countries, mostly in Africa and Asia, can sublicense the formulation for the antiviral pill molnupiravir and start making it, the New York Times reported.
Antibody infusions help keep high-risk COVID-19 patients out of the hospital, but getting the therapy can be a challenge. One U.S. health system has found a creative way to address the problem: home infusions administered by paramedics.
Researchers found that the tactic was feasible, delivering antibody infusions to 144 COVID-19 patients in their homes over three months earlier this year....
Obese people have a tougher time fighting COVID-19, even if they have a milder form of the virus, a new study finds.
Researchers looked at more than 500 patients who tested positive for COVID but didn't require hospitalization. Teens and adults who were overweight or obese had more symptoms, including cough and shortness of breath, than those of normal weight.
Watch closely if your kids appear to have a common cold this fall or winter. It could instead be respiratory syncytial virus, known as RSV, and that makes it more likely to progress to a serious lower lung infection.
RSV is back in force this year after a reprieve while many stayed home last year because of the COVID-19 pandemic, according to experts at Penn State Health.
In some heartening news on the vaccine front, two-thirds of American parents of children ages 5 to 11 plan to get their youngsters vaccinated when COVID-19 shots are approved for that age group, a new survey shows.
"While we're encouraged to see that a majority of parents intend to vaccinate their children against COVID-19 once they are eligible, there is clearly more work to be done to h...
It could be a bad flu season this year — and for a couple of years to come — in places in the United States where COVID-19 restrictions like social distancing and masking have been lifted, researchers warn.
These sorts of measures caused flu cases to decline by more than 60% within the first 10 weeks after COVID-19 lockdowns were implemented in 2020, Columbia University researchers fo...
In a development that could mean Johnson & Johnson might encounter resistance over its application for authorization of a booster shot of its coronavirus vaccine, a new analysis filed by the U.S. Food and Drug Administration on Wednesday suggests the company's evidence may not be strong enough for approval.
A key test used by the company to measure immune response from a booster shot six ...
Experts are warning that the upcoming flu season could be severe as social distancing measures are relaxed across the United States, but a new survey finds that 6 in 10 Americans may delay or skip a flu shot.
However, it also found that 98% of those who got a flu shot last season do plan to get one again this year.
While 82% of the 1,000 adult participants of the online survey sai...
The ongoing coronavirus pandemic has hit minority groups in the United States hard, with significantly more deaths among Black and Hispanic Americans compared with white and Asian Americans, a new study finds.
According to the report, these disparities highlight the need to address ongoing inequities influencing health and longevity in the United States.
People newly infected with COVID-19 might soon have access to what essentially is Tamiflu for the novel coronavirus, a breakthrough that experts say would drastically alter the course of the ongoing pandemic.
At least three contenders are vying to become the first antiviral pill that specifically targets COVID-19, according to reports from drug manufacturers.
Pharmaceutical giant Merck & Co. said Friday that it will seek federal approval for emergency use of its new antiviral pill molnupiravir, after a clinical trial showed the drug halved the risk of hospitalization or death when given to high-risk people shortly after infection with COVID-19.
The new medication is just one of several antiviral pills now being tested in studies, and experts s...
Artificial intelligence (AI) might be able to spot the next virus to jump from animals to humans, Scottish researchers report.
Identifying diseases before they become a threat to humans is challenging, because only a few of the nearly 2 million animal viruses can infect humans. By developing machine learning models, researchers can analyze genetic patterns of viruses that might infect peo...
A new DNA sensor can detect viruses and tell if they are infectious or not in minutes, a new study finds.
The sensor was developed by using DNA technology, and does not require the need to pretreat test samples. Researchers demonstrated this technique with the human adenovirus (which causes colds and flu) and the virus that causes COVID-19.
The future of COVID-19 treatments might include a tiny antibody made by llamas.
British researchers credit a llama named Fifi with their finding.
The investigators said these llama nanobodies, which are also produced by camels, could eventually be produced in a lab and administered by a nasal spray, binding tightly to the COVID-19 virus and neutralizing it.
Antibodies from current COVID-19 vaccines don't bind well to the new variants of the virus, a study finds.
Researchers collected data from previously published papers about the sequence of antibodies produced by the vaccines. They focused on antibodies against the spike protein, a part of the virus that binds to receptors on human cells to infect them. It's the target of most vaccines.
If a person is diagnosed with COVID-19 in the United States right now, it's almost certainly caused by the Delta variant.
The highly transmissible variant, which caused crippling surges in India and Britain this past spring and fueled case spikes in the United States this summer, is now responsible for over 99% of all cases tracked in this country, according to the latest data from the
A study of millions of people vaccinated against COVID-19 has identified those at greatest risk of hospitalization and death after breakthrough infection.
The most vulnerable are those who are immunosuppressed from chemotherapy, a recent bone marrow or solid organ transplant, or HIV/AIDS. Also at risk are people with neurological disorders (such as dementia and Parkinson's disease), nur...
An advisory panel to the U.S. Food and Drug Administration on Friday recommended a third Pfizer-BioNTech COVID vaccine booster shot for all Americans aged 65 or older, as well as for those deemed to be at high risk for severe illness.
According to The New York Times, that vote came after a near unanimous decision (16 to 2) by the same independent panel of experts that said no to ...
In kids and teens, symptoms of long COVID rarely last more than 12 weeks, a new international study reports.
The researchers also found that exposure to the highly contagious Delta variant did not result in more serious disease in children compared to earlier variants, and that most cases of COVID-19 were asymptomatic or mild.
Despite those reassurances, the study did include a trou...
TUESDAY, Sept. 14, 2021 (HealthDay News) -- New data out of Israel, to be published this week, could bolster the notion that a third booster shot of the COVID-19 vaccine significantly lowers a recipient's odds for severe illness.
The data is scheduled to be published in the peer-reviewed New England Journal of Medicine, ahead of this week's U.S. Food and Drug Administration advi...
While in the United States preteens and teens aged 12 to 15 have been eligible for COVID-19 vaccines since the spring, the vaccines are only now becoming available for that age group in the United Kingdom.
According to the Associated Press,on MondayBritain gave its approval for use of the vaccines in children 12 and older as part of a "tool kit" to avoid lockdowns this fall and ...
Monoclonal antibody infusions can help prevent severe COVID-19, but the best protection is to get vaccinated, experts say.
Antibodies are made by the immune system to fight infections.
"The problem is that our immune system takes two to three weeks to make good antibodies," said Dr. Turner Overton, co-director of the Alabama Vaccine Research Clinic at the University of Alabama at Bi...
A high amount of coronavirus in the lungs is a major contributor to death in COVID-19 patients, new research shows.
The findings challenge previous theories that simultaneous infections such as pneumonia or an overreaction of the body's immune system are significant factors in COVID-19 deaths, the researchers noted.
To come to that conclusion, the investigators analyzed bacterial an...
A common bug called respiratory syncytial virus (RSV) circulating among American kids during what's normally its off-season may cause concern if parents don't know how to tell it apart from COVID-19, experts say.
Getting RSV during the summer is unusual, but the U.S. Centers for Disease Control and Prevention recently issued an alert about a rise in RSV cases in Southern states.
Major pandemics aren't all that rare and they're likely to occur more often in the future, a new study claims.
"The most important takeaway is that large pandemics like COVID-19 and the Spanish flu are relatively likely," study co-author William Pan said in a news release from Duke University, where he is an associate professor of global environmental health.